IMMUNITYBIO INC (IBRX) Stock Price & Overview
NASDAQ:IBRX • US45256X1037
The current stock price of IBRX is 8.125 USD. Today IBRX is down by -6.29%. In the past month the price increased by 53.72%. In the past year, price increased by 189%.
IBRX Key Statistics
- Market Cap
- 8.353B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.38
- Dividend Yield
- N/A
IBRX Stock Performance
IBRX Stock Chart
IBRX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IBRX. When comparing the yearly performance of all stocks, IBRX is one of the better performing stocks in the market, outperforming 99.13% of all stocks.
IBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IBRX. Both the profitability and financial health of IBRX have multiple concerns.
IBRX Earnings
On February 23, 2026 IBRX reported an EPS of -0.06 and a revenue of 38.28M. The company beat EPS expectations (37.42% surprise) and beat revenue expectations (1.39% surprise).
IBRX Forecast & Estimates
11 analysts have analysed IBRX and the average price target is 13.06 USD. This implies a price increase of 60.69% is expected in the next year compared to the current price of 8.125.
For the next year, analysts expect an EPS growth of 20.01% and a revenue growth 85.73% for IBRX
IBRX Groups
Sector & Classification
IBRX Financial Highlights
Over the last trailing twelve months IBRX reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS increased by 37.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IBRX Ownership
IBRX Latest News, Press Relases and Analysis
IBRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 406.874B | ||
| AMGN | AMGEN INC | 16.31 | 199.203B | ||
| GILD | GILEAD SCIENCES INC | 16.33 | 178.678B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.5 | 116.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.45 | 80.332B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.48 | 42.526B | ||
| INSM | INSMED INC | N/A | 30.205B | ||
| NTRA | NATERA INC | N/A | 28.081B | ||
| BIIB | BIOGEN INC | 11.5 | 27.132B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.24 | 20.958B | ||
| MRNA | MODERNA INC | N/A | 20.742B | ||
| EXAS | EXACT SCIENCES CORP | 340.31 | 19.757B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.5B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IBRX
Company Profile
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 691 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Company Info
IMMUNITYBIO INC
3530 John Hopkins Court
San Diego CALIFORNIA 92121 US
CEO: Richard Adcock
Employees: 691
Phone: 18446965235
IMMUNITYBIO INC / IBRX FAQ
Can you describe the business of IMMUNITYBIO INC?
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 691 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
What is the stock price of IMMUNITYBIO INC today?
The current stock price of IBRX is 8.125 USD. The price decreased by -6.29% in the last trading session.
Does IBRX stock pay dividends?
IBRX does not pay a dividend.
How is the ChartMill rating for IMMUNITYBIO INC?
IBRX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for IMMUNITYBIO INC?
IMMUNITYBIO INC (IBRX) currently has 691 employees.
What is the market capitalization of IBRX stock?
IMMUNITYBIO INC (IBRX) has a market capitalization of 8.35B USD. This makes IBRX a Mid Cap stock.
Who owns IMMUNITYBIO INC?
You can find the ownership structure of IMMUNITYBIO INC (IBRX) on the Ownership tab.